Draft Health Data Usage Act (GDNG): https://www.bundesgesundheitsministerium.de/service/gesetze-und-verordnungen/detail/gesundheitsdatennutzungsgesetz.html
BfArM Health Research Data Center: https://www.bfarm.de/DE/Das-BfArM/Aufgaben/Forschungsdatenzentrum/_node.html
In June 2023, the German Federal Ministry of Health publicized a draft Health Data Use Act (GDNG) as part of the government’s digitalization strategy for the health sector. The Act aims to facilitate the use of health data for research purposes, which could have positive implications for the pharmaceutical and medical device industry. The GDNG also seeks to prepare Germany for the European Health Data Space (EHDS).
The Act proposes to establish a central data access and coordination point to enable access to research data from various sources, such as existing silos like the cancer registry or health insurance data. The Health Research Data Center of the Federal Institute for Drugs and Medical Devices (BfArM) is expected to act as the intermediary between data users and data holders.
The Act also introduces an “Opt-Out” procedure for data sharing from the electronic patient record (ePA). From 2025, all insured patients will automatically receive a digital file unless they actively object. This procedure is expected to drive the exchange and use of health data and support targeted care.
However, the Act has sparked debates around data privacy and potential misuse. Critics argue that anonymized or pseudonymized data do not sufficiently protect against misuse, and there is a lack of legal obligation to encrypt the data. There are also concerns about the plans to transmit health data of millions of insured individuals not only to the EHDS but also to the USA.
On the other hand, proponents argue that the use of health data is essential for research, innovation, and medical care in the 21st century. They believe that the real ethical question is not how we can justify the use of health data, but rather, how we can justify not using it.
The Act is expected to come into force from January 2024. As the Act progresses, it will be crucial to balance the potential benefits of increased access to health data for research and innovation with the need to protect patient privacy and prevent data misuse.
Share this story...
Lithuania – Leaping into Digital Health Future with RWE and RWD Innovations
RWE 201 - Lithuania – Leaping into Digital Health Future with RWE and RWD Innovations EU Partnership Agreement: https://ec.europa.eu/commission/presscorner/detail/en/ip_22_2547Lithuania is actively implementing Real-World Evidence (RWE) and Real-World Data (RWD) [...]
RWE Guest Post – Does Real-World Evidence Play a Role in G-BA’s Benefit Assessments in Germany?
RWE 201 - RWE Guest Post - Does real-world evidence play a role in G-BA's benefit assessments in Germany? Guest: Anja PownellGerman Market Access – Simplified: https://germanmarketaccesssimplified.com/IntroductionThe German [...]
RWE Guest Post – Germany – From Concept to Evaluation: The Journey of RWE requests by the G-BA
RWE 201 - RWE Guest Post – Germany - From Concept to Evaluation: The Journey of RWE requests by the G-BA Guest: Anja PownellGerman Market Access – Simplified: [...]
Spain – Championing the Ethical and Responsible Use of Real World Data
RWE 201 - Spain – Championing the Ethical and Responsible Use of Real World Data Farmindustria Code of Conduct: https://codigoprotecciondatos.farmaindustria.org/sites/medicamentosinnovadores/docs/PRODF484450.pdfIn 2022, the Spanish Data Protection Agency (AEPD) gave its [...]
EU – RWD/RWE is Embedded into the New EU Medicines Regulations
RWE 201 - EU – RWD/RWE is Embedded into the New EU Medicines Regulations Coming Soon…New EU Medicines Regulations: https://health.ec.europa.eu/medicinal-products/pharmaceutical-strategy-europe/reform-eu-pharmaceutical-legislation_enIn 2023, the European Commission undertook an ambitious overhaul of [...]
EU – EU’s Action Plan for Real-World Data (RWD) & RWE
RWE 201 - EU – EU's Action Plan for Real-World Data (RWD) & RWE The European Union has embarked on an ambitious journey to weave Real World Evidence (RWE) [...]







